Last Updated : May 2, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Xeljanz | Tofacitinib | Arthritis, rheumatoid | List with criteria/condition | Complete | ||
Xeljanz | tofacitinib | Cancelled | ||||
Jinarc | Tolvaptan | Autosomal dominant polycystic kidney disease | Do not list | Complete | ||
Samsca | Tolvaptan | Hyponatremia, non-hypovolemic | Do not list | Complete | ||
Yondelis | Trabectedin | Metastatic Liposarcoma or Leiomyosarcoma | Do not reimburse | Complete | ||
Adtralza | tralokinumab | atopic dermatitis | Do not reimburse | Complete | ||
Adtralza | tralokinumab | atopic dermatitis (AD) | Active | |||
Ralivia | Tramadol hydrochloride | Pain | Do not list | Complete | ||
Tridural | Tramadol hydrochloride | Pain | Do not list | Complete | ||
Zytram XL | Tramadol hydrochloride | Pain, acute | Withdrawn |